Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis
Elisa H. Ignatius, Mahmoud Tareq Abdelwahab, Bronwyn Hendricks, Nikhil Gupte, Kim Narunsky, Lubbe Wiesner, Grace L. Barnes, Rodney Dawson, Kelly E. Dooley, Paolo Denti
Abstract
values were similar to those associated with effective treatment in registrational trials, likely because APT participants were fed with dosing, enhancing pretomanid relative bioavailability and exposures. Pretomanid concentrations with rifabutin were high but in range with prior observations. While pretomanid exposures with rifampin are unlikely to impair efficacy, our data suggest that pretomanid should be taken with food if prescribed with rifampin. (This study has been registered at ClinicalTrials.gov under identifier NCT02256696.).
Topics & Concepts
PharmacokineticsInterimTuberculosisInterim analysisMedicineRandomized controlled trialPharmacologyAntibacterial agentInternal medicineAntibioticsBiologyMicrobiologyPathologyPolitical scienceLawTuberculosis Research and EpidemiologyHIV/AIDS drug development and treatmentPharmacogenetics and Drug Metabolism